INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 414m ago
HOUSE PTR13m ago
SEC 13F13m ago
ROBINHOOD CHAIN13m ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Lee Chan Henry reported ONC

SVP, General Counsel · BeOne Medicines Ltd. · BeOne Medicines Ltd. — Share Option (Right to Buy)

Side
M
Value
—
Shares
2,548
Price
—
Executed
Jan 7, 2026
Disclosed
Jan 9, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 7 executedJan 9, 2026 disclosed

ONC · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
0/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · 2.2% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    4 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ONC

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    15
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$1.45M
    3,965 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    15
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$1.03M
    2,841 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    4
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$460K
    1,280 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    4
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$313K
    880 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    4
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$443K
    1,239 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    15
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$2.96M
    8,148 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    1
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$115K
    320 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    8
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$603K
    1,681 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    0
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Option exercise · 10b5-1 plan
    		M—
    403.4K sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    1
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Option exercise · 10b5-1 plan
    		M$1.14M
    31.0K sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    4
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$512K
    1,440 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    19
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$2.53M
    6,903 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    8
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$845K
    2,331 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    24
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$2.31M
    6,558 sh
    		Oct 13, 2026Oct 15, 2026
    traded Oct 13, 2026
    		+2dSEC FORM 4

    Evidence

    20
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$2.51M
    7,167 sh
    		Oct 13, 2026Oct 15, 2026
    traded Oct 13, 2026
    		+2dSEC FORM 4

    Evidence

    1
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Option exercise · 10b5-1 plan
    		M$1.14M
    31.0K sh
    		Oct 13, 2026Oct 15, 2026
    traded Oct 13, 2026
    		+2dSEC FORM 4

    Evidence

    20
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$3.63M
    10.4K sh
    		Oct 13, 2026Oct 15, 2026
    traded Oct 13, 2026
    		+2dSEC FORM 4

    Evidence

    4
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Option exercise · 10b5-1 plan
    		M—
    403.4K sh
    		Oct 13, 2026Oct 15, 2026
    traded Oct 13, 2026
    		+2dSEC FORM 4

    Evidence

    20
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$2.00M
    5,681 sh
    		Oct 13, 2026Oct 15, 2026
    traded Oct 13, 2026
    		+2dSEC FORM 4

    Evidence

    21
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$445K
    1,260 sh
    		Oct 13, 2026Oct 15, 2026
    traded Oct 13, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001980648-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 7, 2026
    Published
    Jan 9, 2026
    Ingested by INSIDER
    Nov 5, 04:23 UTC
    Last re-read
    Nov 5, 04:23 UTC

    Extracted facts

    Filer
    Lee Chan Henry
    Role
    SVP, General Counsel
    Transaction
    Option exerciseAs filed: “M”
    Asset
    BeOne Medicines Ltd. — Share Option (Right to Buy)
    Ticker
    ONC
    Shares
    2,548
    Price per share
    $0
    Execution date (reported)
    Jan 7, 2026
    Owned after transaction
    118.1K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    What this establishes

    Lee Chan Henry filed this Form 4 reporting a option exercise of ONC on Jan 7, 2026. It became public on Jan 9, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP, General Counsel
    Lee Chan Henrycik:0001980648
    Issuer
    BeOne Medicines Ltd.cik:0001651308

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.